Selective oestrogen receptor modulators in desmoid tumours

Bibliography

• MITLAK BH, COHEN FJ: In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators. Harm. Res. (1997) 48:155–163.
   PubMed Web of Science ®Google Scholar
• •Describes the importance of SERMs as potential substitutes for long-term female hormone replacement therapy.
   Google Scholar
• COSMAN F, LINDSAY R: Selective estrogen receptor modulators: Clinical spectrum. Endocr. Rev (1999) 20:418–434.
   PubMed Web of Science ®Google Scholar
• JORDAN VC: The development of tamoxifen for breast cancer therapy. In long term tamoxifen treatment for breast cancer. VC Jordan (Ed.), University of Wisconsin Press, Madison, WI, USA (1994):3–26.
   Google Scholar
• OSBORNE CK: Drug Therapy: tamoxifen in the treatment of breast cancer. New Engl. J. Med. (1998) 339:1609–1618.
   PubMed Web of Science ®Google Scholar
• •Introduces tamoxifen as a prototype of SERM molecules.
   Google Scholar
• CUMMINGS SR, ECKERT S, KRUEGER KA et al: The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA (1999) 281:2189–2197.
   PubMed Web of Science ®Google Scholar
• FISHER B, COSTANTINO JP, WICKERHAM DL et al.: Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. I Natl. Cancer Inst. (1998) 90:1371–1388.
   PubMed Web of Science ®Google Scholar
• GUSTAFSSON JA: Estrogen receptor 3- a new dimension in estrogen mechanism of action.j Endocrinol. (1999) 163:379–383.
   PubMed Web of Science ®Google Scholar
• TSAI MJ, O'MALLEY BW: Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Ann. Rev Biochem. (1994) 63:451–486.
   PubMed Web of Science ®Google Scholar
• LIEBERMAN BA: The estrogen receptor activity cycle: dependence on multiple protein-protein interactions. Cri. Rev Eukaryot. Gene Expr. (1997) 7:43–59.
   PubMed Web of Science ®Google Scholar
• HALL JM, McDONNELL DP: The estrogen receptor 0-isoform (ER(3) of the human estrogen receptor modulates ERa transcriptional activity and is a key regulator of the cellular response to estrogen and antiestrogens. Endocrinology (1999) 140:5566–5578.
   PubMed Web of Science ®Google Scholar
• PETTERSSON K, GRANDIEN K, KUIPER GG, GUSTAFSSON JA: Mouse estrogen receptor 13 forms estrogen response element-binding heterodimers with estrogen receptor a. Mol. Endocrinol. (1997) 11:1486–1496.
   PubMed Web of Science ®Google Scholar
• COWLEY SM, HOARE S, MOSSELMAN S, PARKER MG: Estrogen receptors a and 13 form heterodimers on DNA. I Biol. Chem. (1997) 272:19858–19862.
   Web of Science ®Google Scholar
• FAWELL SE, LEES JA, WHITE R, PARKER MG: Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor. Cell (1990) 60:953–962.
   PubMed Web of Science ®Google Scholar
• YANG NN, VENUGOPALAN M, HARDIKER S, GLASEBROOK A: Identification of a estrogen response element activated by metabolites of 1713-estradiol and raloxifene. Science (1996) 273:1222–1225.
   PubMed Web of Science ®Google Scholar
• TORA L, WHITE J, BROU C et al: The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell (1989) 59:477–487.
   PubMed Web of Science ®Google Scholar
• TZUKERMAN MT, ESTY A, SANTISO-MERE D et al: Human estrogen receptor transactiyational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol. Endocrinol. (1994) 8:21–30.
   PubMed Web of Science ®Google Scholar
• BERRY M, METZGER D, CHAMBON P: Role of the two activating domains of the estrogen receptor in the cell-type and promoter-context dependent agonist activity of the antiestrogen 4-hydroxytamoxifen. EMBO J. (1990) 9:2811–2818.
   PubMed Web of Science ®Google Scholar
• WEBSTER NJG, GREENS, TASSET D,PANGLIKITMONGKOL M, CHAMBON P: The transcriptional activation function located in the hormone binding domain of the human estrogen receptor is not encoded in a single exon. EMBO J. (1989) 8:1441–1446.
   PubMed Web of Science ®Google Scholar
• McKENNA NJ, LANZ RB, O'MALLEY BW: Nuclear receptor coregulators: cellular and molecular biology Endocr. Rev. (1999) 20:321–344.
   Google Scholar
• GLASS CK, ROSENFELD MG: The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. (2000) 14:121–141.
   PubMed Web of Science ®Google Scholar
• WEBB P, LOPEZ GN, UHT RIVI, KUSHNER PJ: Tamoxifen activation of the estrogen receptor/AP-1 pathway. Potential origin for the cell specific estrogen-like effects of antiestrogens. Mol. Endocrinol. (1995) 9:443–456.
   Google Scholar
• SAVILLE B, WORMKE M, WANG F et al.: Ligand, cell- and estrogen receptor subtype (a/0)-dependent activation at GC-rich (Sp].) promoter elements. J. Biol. Chem. (2000) 275:5379–5387.
   Google Scholar
• McDONNEL DP: The molecular pharmacology of SERIVIs. Trends Endocrinol. Metab. (1999) 10:301–311.
   PubMed Web of Science ®Google Scholar
• KATZENELLENBOGEN JA, O'MALLEY BW, KATZENELLENBOGEN BS: Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell-and promoter-specific action of these hormones. Mol. Endocrinol. (1996) 10:119–131.
   PubMed Web of Science ®Google Scholar
• MARTIN PM, BERERTHOISIS Y, JENSEN EV: Binding of antiestrogens exposes an occult antigenic determinant in the human estrogen receptor. Proc. Natl. Acad. Sci. USA (1998) 85:2533–2537.
   Google Scholar
• McDONNELL DP, CLEMM DL, HERMANN T, GOLDMAN ME, PIKE JW: Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol. Endocrinology (1995) 9:659–669.
   PubMed Web of Science ®Google Scholar
• BRZOZOWSKI AM, PIKE AC, DAUTER Z et al.: Molecular basis of agonism and antagonism in the estrogen receptor. Nature (1997) 389: 753–758.
   PubMed Web of Science ®Google Scholar
• •Describes the molecular basis of agonism and antagonism in the ER.
   Google Scholar
• SHIAU AK, BASTAD D, LORIA PM et al.: The structural basis of estrogen receeptoricoactivator recognition and the antagonism of this interaction by tamoxifen. Cell (1998) 95:927–937.
   PubMed Web of Science ®Google Scholar
• PAIGE LA, CHRISTENSEN DJ, GRON H et al.: Estrogen receptor modulators each induce distinct conformational changes in ER a and ER 0. Proc. Natl. Acad. Sci. USA (1999) 96:3999–4004.
   PubMed Web of Science ®Google Scholar
• PIKE AC, BRZOZOWSKI AM, HUBBARD RE et al: Structure of the ligand-binding domain of estrogen receptor 13 in the presence of a partial agonist and a full antagonist. EMBO J. (1999) 18:4608–4618.
   PubMed Web of Science ®Google Scholar
• JACKSON TA, RICHER JK, BAIN DL, TAKIMOTO GS, TUNG L, HORWITZ KB: The partial agonist activity of antagonists-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and corepressors N-CoR or SMRT. Mol. Endocrinol. (1997) 11:693–705.
   PubMed Web of Science ®Google Scholar
• LAVINSKY RIVI, JEPSEN K, HEINZEL T et al.: Diverse signalling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc. Natl. Acad. Sci. USA (1998) 95:2920–2925.
   PubMed Web of Science ®Google Scholar
• ENDOTH H, MARUYAMA K, MASUHIRO Y et al.: Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor a. Mol. Cell. Biol. (1999) 19:5363–5372.
   PubMed Web of Science ®Google Scholar
• SHANG Y, BROWN M: Molecular determinants for the tissue specificity of SERMs. Science (2002) 295:2465–2468.
   PubMed Web of Science ®Google Scholar
• HALL JM, McDONNEL DP: The estrogen receptor 0-isoform (ERB) of the human estrogen receptor modulates ERa transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology (1999) 140:5566–5578.
   PubMed Web of Science ®Google Scholar
• PAECH K, WEBB P, KUIPER GG et al: Differential ligand activation of estrogen receptors ERa and ERI3 at AP-1 sites. Science (1997) 277:1508–1510.
   PubMed Web of Science ®Google Scholar
• •Describes the importance of the ligand and the different regulatory gene sequences for the activation or inactivation of ERs and for gene expression.
   Google Scholar
• KUIPER GGJM, LEMMEN JG, CARLSSON B et al: Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor 0. Endocrinology (1998) 139:4252–4263.
   PubMed Web of Science ®Google Scholar
• BRODSKY JT, GORDAN MS, HAJDU SI, BURT M: Desmoid tumors of the chest wall. A locally recurrent problem. Thorac. Cardiovasc. Surg. (1992) 104:900–903.
   Web of Science ®Google Scholar
• HALATA MS, MILLER J, STONE RK: Gardner syndrome. Early presentation with a desmoid tumor. Discovery of multiple colonic polyps. Clia Pediam (1989) 28:538–540.
   Google Scholar
• MIYAKI M, KONISHI M, KIKUCHI-YANOSHITA R et al.: Coexistence of somatic and germ-line mutations of APC gene in desmoid tumors from patents with familial adenomatous polyposis. Cancer Res. (1993) 53:5079–5082.
   PubMed Web of Science ®Google Scholar
• ALMAN BA, LI C, PAJERSKI ME, DIAZ-CANO S, WOLFE HJ: Increased 0-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am. J. Pathol. (1997) 151:329–334.
   PubMed Web of Science ®Google Scholar
• GIAROLA M, WELLS D, MONDINI P et al: Mutations of adenomatous polyposis coli (APC) gene are uncommon in sporadic desmoid tumours. BE J. Cancer (1998) 78:582–587.
   Web of Science ®Google Scholar
• •Describes the mutational analysis in sporadic desmoid tumours.
   Google Scholar
• SAITO T, ODA Y, TANAKA K et al: 0-catenin nuclear expression correlates with cyclin D1 overexpression in sporadic desmoid tumors. J. Pathol. (2001) 195:222–228.
   PubMed Web of Science ®Google Scholar
• •Describes the mutational analysis in sporadic desmoid tumours.
   Google Scholar
• SHITOH K, KONISHI F, IIJIMA T et al: A novel case of sporadic desmoid tumor with mutation of the 0-catenin gene. Clin. Pathol. (1999) 52:695–696.
   PubMed Web of Science ®Google Scholar
• TEJPAR S, NOLLET F, LI C et al: Predominance of 0-catenin mutations and 0-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene (1999) 18:6615–6620.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ-BIGAS MA, MAHONEY MC, KARAKOUSIS CP, PETRELLI NJ: Desmoid tumor in patients with familial adenomatous polypoisis. Cancer (1994) 74:1270–1274.
   PubMed Web of Science ®Google Scholar
• JONES IT, JAGELMAN DG, FAZIO VW, LAVERY IC, WEAKLEY FL, McGANNON E: Desmoid tumors in familial polyposis coli. Ann. Surg. (1986) 204:94–97.
   PubMed Web of Science ®Google Scholar
• BUSSEY HI: Extracolonic lesions associatedwith polyposis coli. Proc. R. Soc. Med. (1972) 65:294.
   PubMedGoogle Scholar
• JARVINEN HJ: Desmoid disease as part of familial adenomatous polyposis coli. Acta. Chir. Scand. (1987) 153:374-383. 1465
   Google Scholar
• MIDDLETON SB, FRAYLING IM, PHILLIPS RK: Desmoids in familial adenomatous polyposis are monoclonal proliferations. Br. J. Cancer (2000) 82:827–832.
   PubMed Web of Science ®Google Scholar
• LEWIS JJ, BOLAND PJ, LEUNRY DH, WOODRUFF JM, BRENNAN MF: The enigma of desmoid tumors. Ann. Surg. (1999) 299:866–872.
   Google Scholar
• CLARK SK, SMITH TG, KATZ DE et al:Identification and progression of a desmoid precursor lesion in patients with familial adenomatous polyposis. BE J. Surg. (1998) 85:970–973.
   PubMed Web of Science ®Google Scholar
• •Describes the development of a desmoid tumour in FAP patients.
   Google Scholar
• MIDDLETON SB, CLARK SK, MATRAVERS P et al: Stepwise progression in the development of desmoids in familial adenomatous polyposis. Dis. Colon Rectum (2003) 46:481–485.
   PubMed Web of Science ®Google Scholar
• •Describes the development of a desmoid tumour in FAP patients.
   Google Scholar
• POSNER MC, SHIU MH, NEWSOME JL, HAFDU SI, GAYNOR JL, BRENNAN MF: The desmoid tumor. Not a benign disease. Arch. Surg. (1989) 124:191–196.
   PubMed Web of Science ®Google Scholar
• McADAM WA, GOLIGHER JC: The occurrence of desmoids in patients with familial polyposis coli. BE J. Surg. (1970) 57:618–631.
   PubMed Web of Science ®Google Scholar
• HARVEY JC, QUAN SHQ, FORTNER JG: Gardner's syndrome complicated by mesenteric desmoid tumors. Surgery (1979) 85:475–477.
   PubMed Web of Science ®Google Scholar
• JONES IT, JAGELMAN DG, FAZIO VW, LAVERY IC, WEAKLEY FL, McGANNON E: Desmoid tumors in familial polyposis coli. Ann. Surg. (1986) 204:94–97.
   PubMed Web of Science ®Google Scholar
• WADDELL WR: Treatment of intra-abdominal and abdominal wall desmoid tumors with drugs that affect the metabolism of cyclic 3',5'-adenosine monophosphate. Ann. Surg. (1975) 181:299–302.
   PubMed Web of Science ®Google Scholar
• LOPEZ R, KEMALYAN N, MOSELEY HS, DENNIS D, VETTO RM: Problems in diagnosis and management of desmoid tumors. Am. Surg. (1990) 159:450–453.
   Google Scholar
• GURBUZ AK, GIARDIELLO FM, PETERSEN GM et al: Desmoid tumors in familial adenomatous polyposis. Gut (1994) 35:377–381.
   PubMed Web of Science ®Google Scholar
• LYNCH HT, FITZGIBBONS R: Surgery, desmoid tumors and familial adenomatous polyposis: case report and literature review. Am. J. Gastroenterol. (1996) 91:2598–2601.
   PubMed Web of Science ®Google Scholar
• KLEMMER S, PASCOE L, DECOSSE J: Occurrence of desmoids in familial adenomatous polyposis of the colon. Am. .1 Med. Genet. (1987) 28:385–392.
   PubMed Web of Science ®Google Scholar
• CASPARI R, OLSCHWANG S, FRIEDL W et al.: Familial adenomatous polyposis: desmoid tumors and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum. Mol. Genet. (1995) 4:337–340.
   PubMed Web of Science ®Google Scholar
• •Describes the mutational analysis in desmoid tumours from FAP patients.
   Google Scholar
• PALMIROTTA R, CURIA MC, ESPOSITO DL et al: Novel mutations and inactivation of both alleles of APC gene in desmoid tumors. Hum. Mol. Genet. (1995) 4:1979–1981.
   PubMed Web of Science ®Google Scholar
• •Describes the mutational analysis in desmoid tumours from FAP patients.
   Google Scholar
• ZAYIT I, DIHMIS C: Familial multicentric fibromatosis-desmoids. Cancer (1989) 24:786–796.
   Google Scholar
• OZUNER G, HULL TL: Familial desmoids in association with adrenal and ovarian masses and leiomyomas: report of three cases. Dis. Colon. Rectum. (1999) 42:529–532.
   PubMed Web of Science ®Google Scholar
• EINSTEIN DM, TAGLIABUE JR, DESAI RK: Abdominal desmoids: CT findings in 25 patients. Am. J. Roentgenol (1991) 157:275–279.
   PubMed Web of Science ®Google Scholar
• CLARK SK, PHILLIPS RKS: Desmoids in familial adenomatous polyposis. Br. J. Surg. (1996) 83:1494–1504.
   PubMed Web of Science ®Google Scholar
• COTRAN RS, KUMAR V, COLLINS T: Robbins pathologic bash of disease (6th Edition). Saunders Company, Philadelphia, PA, USA (1998):1476.
   Google Scholar
• SALLOUM H, KANITAKIS J, CHOUVET B, GRIMAND P, CLAUDY A: Extrabdominal desmoid tumor. Microscopic aspects and histogenesis. Ann. Dermatol Venereol (1993) 120:685–688.
   PubMed Web of Science ®Google Scholar
• PRITCHARD DJ, SOULE EH, TAYLOR WF, IVINS JC: Fibrosarcoma - a clinicopathologic and statistical study of 199 tumors of the soft tissues of the extremities and trunk. Cancer (1974) 33:888–897.
   PubMed Web of Science ®Google Scholar
• TORRES D: Multiple sebaceous tumours.Arch. Dermatol (1968) 98:549.
   PubMed Web of Science ®Google Scholar
• SARNO RC, KLAUBER G, CARTER BL: Computer assisted tomography of urachal abnormalities. I Comput. Assist. Tomogr. (1983) 7:674–676.
   PubMed Web of Science ®Google Scholar
• O'KEEFE F, KIM EE, WALLACE S: Magnetic resonance imaging in aggressive fibromatosis. Clin. Radial. (1990) 42:170–173.
   PubMed Web of Science ®Google Scholar
• EASTER DW, HALASZ NA: Recent trends in the managment of desmoid tumors. Summary of 19 cases and review of the literature. Ann. Surg. (1989) 210:765–769.
   PubMed Web of Science ®Google Scholar
• CORBEL L, SOUISSI M, CHRETIEN Y, DUFOUR B: Desmoid tumor of the mesentery. An uncommon cause of ureteral obstruction. Radial. (1992) 73:669–672.
   Google Scholar
• WEISS AJ, LACKMAN RD: Low dose chemotherapy of desmoid tumors. Cancer (1989) 64:1192–1194.
   PubMed Web of Science ®Google Scholar
• REITAMO JJ, SCHEININ TM, HAYRY P: The desmoid tumors: new aspects in the cause, pathogenesis and treatment of the desmoid tumor. Am. J. Surg. (1986) 151:230–237.
   PubMed Web of Science ®Google Scholar
• KHORSAND J, KARAKOUSIS CP: Desmoid tumors and their managment. Am. J. Surg. (1985) 149:215–218.
   PubMed Web of Science ®Google Scholar
• McKINNON JG, NEIFELD JP, KAY S, PARKER GA, FOSTER WC, LAWRENCE W: Management of desmoid tumors. Surg. Gyrrecol Obstet. (1989) 169:104–106.
   PubMedGoogle Scholar
• REITAMO JJ, HAYRY P, NYKYRI E, SAXEN E: The desmoid tumor. Incidence, sex, age, and anatomical distribution in the Finnish population. Am. I Clin. Pathol (1982) 77:665–673.
   Google Scholar
• HAYRY P, REITAMO JJ, TOTTERMAN S, HPFNER-HALLIKAINEN D, SIVULA A: The desmoid tumors. II. Analysis of factors possibly contributing to the etiology and growth behaviour. Am. I Clin. Pathol (1982) 77:674–680.
   Google Scholar
• •Describes the higher incidence of desmoid tumours in women and the importance of sex hormones.
   Google Scholar
• DAHN I, JONSSON N, LUNDH G: Desmoid tumors. A series of 33 cases. Acta Chi]: Scand. (1963) 126:305–314.
   Google Scholar
• WILCKEN N, TATTERSALL MH: Endocrine therapy for desmoid tumors. Cancer (1991) 68:1384–1388.
   PubMed Web of Science ®Google Scholar
• DHINGRA K: Antiestrogens-tamoxifen, SERMs and beyond. Invest. New Drugs (1999) 17:285–311.
   PubMed Web of Science ®Google Scholar
• SVANVIK J, KNUTSSON F, JANSSON R, EKMAN H: Desmoid tumor in the abdominal wall after treatment with high dose estradiol for prostatic cancer. Acta Our. Scand. (1982) 148:301–303.
   Google Scholar
• HEISKANEN I, JARVINEN HJ: Occurrence of desmoid tumors in familial adenomatous polyposis and results of treatment. Int. J. Colorectal Dis. (1996) 11:157–162.
   PubMed Web of Science ®Google Scholar
• TSUKADA K, CHURCH JM, JAGELMAN DG et al.: Noncytotoxic drug therapy for intra-abdominal desmoid tumors in patients with familial adenomatous polyposis. Dis. Colon Rectum (1992) 35:29–33.
   PubMed Web of Science ®Google Scholar
• WADDELL WR, KIRSCH WM: Testolactone, sulindac, warfarin and vitamin K for unresectable desmoid tumors. Am. J. Surg. (1991) 161:416–421.
   PubMed Web of Science ®Google Scholar
• KLEIN WA, MILLER HH, ANDERSON M, DECOSSE JJ: The use of indometacin, sulindac, and tamoxifen for the treatment of desmoid tumors associated with familial polyposis. Cancer (1987) 60:2863–2868.
   PubMed Web of Science ®Google Scholar
• SEITER K, KEMENY N: Successful treatment of a desmoid tumor with doxorubicina. Cancer (1993) 71:2242–2244.
   PubMed Web of Science ®Google Scholar
• HAMILTON L, BLACKSTEIN M, BERK T et al.: Chemotherapy for desmoid tumors in association with familial adenomatous polyposis: a report of three cases. Can. J. Surg. (1996) 39:247–252.
   PubMed Web of Science ®Google Scholar
• PENNA C, TIRET E, PARC R et al.: Operation and abdominal desmoid tumors in familial adenomatous polyposis. Surg. Cynecol. Obstet. (1993) 177:263–268.
   PubMedGoogle Scholar
• PATEL SR, EVANS HL, BENJAMIN RS: Combination chemotherapy in adult desmoid tumors. Cancer (1993) 72:3244–3247.
   PubMed Web of Science ®Google Scholar
• PICARIELLO L, BRANDI ML, FORMIGLI L et al.: Apoptosis induced by sulindac sulfide in epithelial and mesenchymal cells from human abdominal neoplasms. Eur. j Pharmacol. (1998) 360:105–112.
   PubMed Web of Science ®Google Scholar
• KINZBRUNNER B, RITTER S, DOMINGO J, ROSENTHAL CJ: Remission of rapidly growing desmoid tumors after tamoxifen therapy. Cancer (1983) 52:2201–2204.
   PubMed Web of Science ®Google Scholar
• SPORTIELLO DJ, HOOGERLAND DL: A recurent pelvic desmoid tumor successfully treated with tamoxifen. Cancer (1999) 67:1443–1446.
   Google Scholar
• PROCTER H, SINGH L, BAUM M, BRINKLEY D: Response of multicentric desmoid tumors to tamoxifen. BE Surg. (1987) 74:401.
   PubMed Web of Science ®Google Scholar
• BUS PJ, VERSPAGET HW, VAN KRIEKEN HJM et al.: Treatment of mesenteric desmoid tumors with the anti-oestrogenic agent toremifene: case histories and an overview of the literature. Eur. Castroenterol. Hepatol. (1999) 11:1179–1183.
   Google Scholar
• BAUERNHOFER T, STOGER H, SCHMID M et al.: Sequential treatment of recurrent mesenteric desmoid tumor. Cancer (1996) 77:1061–1065.
   PubMed Web of Science ®Google Scholar
• TONELLI F, FICARI F, VALANZANO R, BRANDI ML: Treatment of desmoids and mesenteric fibromatosis in familial adenomatous polyposis with raloxifene. Tumori (2003) 89:391–396.
   PubMed Web of Science ®Google Scholar
• •Describes the results of the treatment of desmoid tumours in FAP patients with raloxifene.
   Google Scholar
• DELMAS PD, BJARNASON NH, MITLAK BH: Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl. Med. (1997) 337:1641–1647.
   PubMed Web of Science ®Google Scholar
• COHEN I, ROSEN DJ, SHAPIRA J et al.: Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, posmenopausal breast cancer patients. Gynecol. Oncol. (1994) 52:185–190.
   PubMed Web of Science ®Google Scholar
• KEDAR RP, BOURNE TH, POWLES TJ et al.: Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet (1994) 343:1318–1321.
   PubMed Web of Science ®Google Scholar
• FISHER B, COSTANTINO JP, REDMOND CK, FISHER ER, WICKERHAM DL, CRONIN WM: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the national Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Nati Cancer. Inst. (1994) 86:527–537.
   PubMed Web of Science ®Google Scholar
• FISHER B, COSTANTINO JP, WICKERHAM DL et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Nati Cancer Inst. (1998) 90:1371–1388.
   PubMed Web of Science ®Google Scholar
• PICARIELLO L, FIORELLI G, BEN VENUTI S et al.: In vitro bioeffects of the antiestrogen LY117018 on desmoid tumor and colon cancer cells. Anti-Cancer Res. (1997) 17:2099–2104.
   Google Scholar
• BAKER VL, DRAPER M, PAUL S et al.: Reproductive endocrine and endometrial effects of raloxifene hydrocloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. j. Endocrinol. Metab. (1998) 83:6–13.
   PubMed Web of Science ®Google Scholar
• TONELLI F, VALANZANO R, BRANDI ML: Pharmacological treatment of desmoid tumors in familial adenomatous polyposis: results of an in vitro study. Surgery (1994) 115:473–479.
   PubMed Web of Science ®Google Scholar
• LIM CL, WALKER MJ, METHA RR, DAS GUPTA TK: Estrogen and antiestrogen binding sites in desmoid tumors. Eur. J. Cancer Clin. Oncol. (1986) 22:583–587.
   PubMedGoogle Scholar
• SERPELL JW, PADDLE-LEDINEK JE, JOHNSON WR: Modification of growth of desmoid tumors in tissue culture by anti-estrogenic substances: a preliminary report. Aust. NZI. Surg. (1996) 66:457–463.
   PubMed Web of Science ®Google Scholar
• EARLY BREAST CANCER TRIALLISTS: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomised trials among 28896 women. N Engl. J. Med. (1988) 319:1681–1690.
   PubMedGoogle Scholar
• COLLETTA A, WAKEFIELD L, HOWELL F et al. Antiestrogens induce the secretion of active transforming growth factor 13 from human foetal fibroblasts. Br. J. Cancer (1990) 62:405–409.
   PubMed Web of Science ®Google Scholar
• MOSES H L, YANG EY, PIETENPOL JA: TGF-I3 stimulation and inhibition of cell proliferation: new mechanistic insights. Cell (1990) 63:245–247.
   PubMed Web of Science ®Google Scholar
• BROOKS VL, EBBS SR, COLLETTA AA, BAUM M: Desmoid tumors treated with triphenylethylenes. Eur. J. Cancer (1992) 28A:1014–1018.
   PubMed Web of Science ®Google Scholar
• CHAUDHURI P, WALKER M, BEATTIE C, DAS GUPTA T: Presence of steroid receptors in human soft tissue sarcomas of diverse histological origin. Cancer Res. (1980) 40:861–865.
   PubMed Web of Science ®Google Scholar
• WEISS S, LANGLOSS J, SHMOOKLER B et al.: Estrogen receptor protein in bone and soft tissue tumors. Laboratory Investigation (1986) 54:689–694.
   PubMed Web of Science ®Google Scholar
• LOCCI P, BELLOCCHIO S, LILLI C et al.: Synthesis and secretion of transforming growth factor-I3 1 by human Expert Op/n. Investig. Drugs (2004) 13(11)1467 desmoid fibroblast cell line and its modulation by toremifene. J. Interferon Cytokine Res. (2001) 21:961–970.
   Google Scholar
• NAITO Y, OHORI K, TANAKA M et al.: Collagen end elastin synthesis by desmoid tumor in vitro. Pathol Int. (1998) 48:603–610.
   PubMed Web of Science ®Google Scholar
• ETTINGER B, BLACK DM, MITLAK BH et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA (1999) 282:637–645.
   PubMed Web of Science ®Google Scholar
• YAFFE K, KRUEGER K, SARKAR S et al: Multiple outcomes of raloxifene evaluation investigators: cognitive function in postmenopausal women treated with raloxifene. N Engl. J. Med. (2001) 344:1207–1213.
   PubMed Web of Science ®Google Scholar
• SHIAU AK, BASTARD D, LORIA PM et al: The structural basis of estrogen receptoricoactivator recognition and the antagonism of this interaction by tamoxifen. Cell (1998) 95:927–937.
   PubMed Web of Science ®Google Scholar
• NORRIS JD, PAIGE LA, CHRISTENSEN DJ et al.: Peptide antagonists of the human estrogen receptor. Science (1999) 285:744-746. Affiliation
   Google Scholar